A new publication dated June 17, 2026 appeared in The Journal of Pediatrics. The article is titled "Pediatric Neuroinflammatory and Neuropsychiatric Syndromes Associated with Dupilumab Treatment for Atopic Dermatitis." This entry documents the publication's release in the journal on the stated date. No findings, conclusions, or outcome data from the article are provided in this event record. The publication concerns dupilumab, a treatment used for atopic dermatitis, rather than KPV directly. KPV remains classified as an unapproved compound intended for research use only. This brief does not summarize or interpret any results, associations, or safety signals described in the article. Readers seeking the full content of the study should consult the original source directly. No efficacy, benefit, or harm can be inferred from this listing alone. This record exists solely to note that the publication has been indexed and is available for reference. For general background on KPV and its research context, readers can consult the compound overview.
New Publication Reviews Pediatric Neuropsychiatric Cases in Dupilumab Study
Drafted by an automated content engine from FDA, PubChem, ClinicalTrials.gov, NIH DSLD, and Open Beauty Facts data.
Source: https://pubmed.ncbi.nlm.nih.gov/42309223/